Blood-Brain Barrier (BBB) pharmacoproteomics: Reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 579-588

  Uchida, Yasuo ^a   Ohtsuki, Sumio ^a   Kamiie, Junichi ^b   Terasaki, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b AZABU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIAZEPAM; DIGITOXIN; DIGOXIN; GLYCOPROTEIN P; GLYCOPROTEIN P 11; INDINAVIR; LOPERAMIDE; LORATADINE; MULTIDRUG RESISTANCE 1A PROTEIN; PACLITAXEL; QUINIDINE; QUINIDINE SULFATE; RISPERIDONE; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINBLASTINE SULFATE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CELL TRANSPORT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG TRANSPORT; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PHARMACOPROTEOMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEPTOR INTRINSIC ACTIVITY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; DOGS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; KIDNEY; LLC-PK1 CELLS; MALE; MICE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHARMACEUTICAL PREPARATIONS; PROTEOMICS; QUINIDINE; SWINE;

EID: 80054792485     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184200     Document Type: Article

References (34)

1. Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18:1660-1668. (Pubitemid 34020420)
2. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
3. Chen C, Hanson E, Watson JW, and Lee JS (2003) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31:312-318. (Pubitemid 36249686)
4. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174. (Pubitemid 40023528)
5. Enokizono J, Kusuhara H, Ose A, Schinkel AH, and Sugiyama Y (2008) Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36:995-1002. (Pubitemid 351717455)
6. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, and de Morais SM (2008) In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268-275. (Pubitemid 351185738)
7. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, and Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353-362.
8. Fridén M, Gupta A, Antonsson M, Bredberg U, and Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719. (Pubitemid 47296068)
9. Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, and Antonsson M (2009) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233-6243.
10. Hammarlund-Udenaes M, Fridén M, Syvänen S, and Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25:1737-1750.
11. Hawkins BT, Sykes DB, and Miller DS (2010) Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 30:1417-1425.
12. Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, Vaalburg W, and Franssen EJ (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418. (Pubitemid 28360563)
13. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478. (Pubitemid 30183327)
14. Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, Kamiie J, and Terasaki T (2011) Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 100:3939-3950.
15. Kakee A, Terasaki T, and Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277:1550-1559. (Pubitemid 27167171)
16. Kalvass JC, Maurer TS, and Pollack GM (2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666. (Pubitemid 46513270)
17. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/ MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469-1483.
18. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, and van Tellingen O (2004) The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 53:173-178. (Pubitemid 38186997)
19. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294. (Pubitemid 28067324)
20. Kusuhara H and Sugiyama Y (2009) In vitro-in vivo extrapolation of transportermediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37-52.
21. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, and Sugiyama Y (1997) P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283:574-580. (Pubitemid 27514613)
22. Liu X, Chen C, and Smith BJ (2008) Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 325:349-356. (Pubitemid 351574780)
23. Maurer TS, Debartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181. (Pubitemid 40023529)
24. Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31:246-254.
25. Ose A, Kusuhara H, Endo C, Tohyama K, Miyajima M, Kitamura S, and Sugiyama Y (2010) Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos 38:168-176.
26. Polli JW, Humphreys, JE, Wring SA, Burnette TC, Read KD, Hersey A, Butina D, Bertolotti L, Pugnaghi F, and Serabjit-Singh C (2000) A comparison of Madin- Darby canine kidney cells and bovine brain endothelial cells as a blood-brain barrier screen in early drug discovery, in Progress in the Reduction, Refinement and Replacement of Animal Experimentation (Balls M, van Zeller AM, and Halder ME eds) pp 271-289, Elsevier Science B.V., Amsterdam, The Netherlands.
27. Shirasaka Y, Sakane T, and Yamashita S (2008) Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 97:553-565.
28. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, et al. (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518-1535.
29. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, and Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205-213. (Pubitemid 46956363)
30. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B, Knudsen GM, and Hammarlund-Udenaes M (2009) Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635-643.
31. Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, and Sugiyama Y (2010) Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 27:442-446.
32. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
33. Wijnholds J, deLange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, and Borst P (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the bloodcerebrospinal fluid barrier. J Clin Invest 105:279-285. (Pubitemid 30094447)
34. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for p-glycoprotein- mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735. (Pubitemid 32187340)